SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy gains on getting US FDA approval for New-Jersey based Ohm Laboratories

11 Oct 2013 Evaluate

Ranbaxy Laboratories is currently trading at Rs. 400.80, up by 7.65 points or 1.95 % from its previous closing of Rs. 393.15 on the BSE.

The scrip opened at Rs. 432.45 and has touched a high and low of Rs. 435.00 and Rs. 397.15 respectively. So far 1322628 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 559.80 on 08-Nov-2012 and a 52 week low of Rs. 253.95 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 399.45 and Rs. 353.35 respectively. The current market cap of the company is Rs. 16988.65 crore.

The promoters holding in the company stood at 63.51 % while Institutions and Non-Institutions held 19.46 % and 14.29 % respectively.

Ranbaxy has received an Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its New-Jersey based Ohm Laboratories. An EIR signifies that all issues and concerns of non-compliance observed by the FDA in its December audits have been rectified satisfactorily.

Ohm Labs is currently the only facility certified for this purpose as Ranbaxy’s other units at Paonta Sahib, Dewas and Mohali (all in India) have been barred following deviations from compliance norms.

Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×